An ANDA Update. June 2004 Bulletin 04-50
|
|
- Russell Heath
- 6 years ago
- Views:
Transcription
1 June 2004 Bulletin If you have questions or would like additional information on the material covered in this Bulletin, please contact one of the authors: Mark R. Shanks Toni-Junell Herbert David J. Bloch Patricia A. Johnson or the Reed Smith attorney with whom you regularly work This bulletin is presented for informational purposes and is not intended to constitute legal advice. Reed Smith LLP All Rights Reserved. Reed Smith refers to Reed Smith LLP, a limited liability partnership formed in the state of Delaware. An ANDA Update Since enactment in 1984 of the Hatch-Waxman Act, which created certain procedural incentives designed to encourage generic drug companies to enter the pharmaceutical market, confusion arose around the interpretation of many of the core provisions involving the FDA approval process and application in a litigation proceeding. In June 2003, in an effort to clarify matters and end some of the confusion, the FDA promulgated its own rules which became effective on August 19, 2003, with a compliance date of December 18, Congress returned to the generic drug issue when it passed the Medicare Prescription Drug, Improvement, and Modernization Act. 1 It was signed by President Bush December 8, 2003 and became effective January 8, The law s impact goes beyond the obvious Medicare issues, and makes noteworthy changes to the Hatch-Waxman Act. In particular, Section (j) of the law deals with the portion of Hatch-Waxman governing the approval process for abbreviated new drug applications, commonly known as ANDAs. Since the enactment of the Hatch-Waxman changes, the FDA has rescinded those regulatory provisions that have been covered by Congress recent amendments. From the perspective of the brand drug manufacturers, the most significant changes to the generic drug approval process, and its attendant patent dispute, include: There is no extension of the 30-month period as applicant need no longer make a new Paragraph IV Certification for any patent added to the Orange Book subsequent to filing an ANDA application. Applicant cannot shorten the 30-month period by amending its application to add a different drug. Applicant is required to provide notice to the patent owner of its ANDA filing within 20 days of receiving notice from the FDA of the filing of its application. If applicant amends or supplements its application, it must provide notice even if prior notice was given. Declaratory judgment actions and counterclaims seeking removal of a patent from the Orange Book are now available to the applicant. Declaratory judgment actions are available only to the extent consistent with the Constitution. LONDON NEW YORK LOS ANGELES SAN FRANCISCO WASHINGTON, D.C. PHILADELPHIA PITTSBURGH OAKLAND PRINCETON NORTHERN VA WILMINGTON NEWARK MIDLANDS, U.K. CENTURY CITY RICHMOND HARRISBURG WESTLAKE VILLAGE r e e d s m i t h. c o m
2 Money damages are not available in a de-listing counterclaim. Applicant can forfeit its 180-day exclusivity period if: applicant fails to market the drug within certain specified time frames; applicant withdraws its application; applicant amends or withdraws its Paragraph IV Certification; applicant fails to obtain tentative approval within 30 months from the application s filing date; applicant enters into an agreement that is found by the FTC or court to have violated antitrust laws; or expiration of all patents listed in the application. If the 180-day exclusivity period is forfeited by the first Applicant, it is not available for any applicant. Only one exclusivity period is available. A court decision is statutorily defined as a decision from which no appeal has been or can be taken (other than a petition to the Supreme Court for a Writ of Certiorari). From the perspective of generic drug manufacturers, the most significant changes include: Give notice to each patent owner whose patent is the subject of the Paragraph IV ANDA within 20 days after the date of the postmark of the FDA s notice of the ANDA filing. ANDA applicant may not amend or supplement an application to reference any other different listed drug. Only one 30-month stay is permitted for each application. A declaratory judgment action ( DJ action ) is available to an applicant who is not sued to the extent consistent with the Constitution within 45 days after the notice of the filing is received by the owner of the patent that is the subject of the application: if applicant offers confidential access to the application to patent owner; or, if because Paragraph IV Certification is only based on invalidity of patent, offer is not required. Counterclaim is available to applicant seeking an order for deletion of patent from the Orange Book on the basis that the patent does not claim the approved drug or approved method of use. Money damages are prohibited in a case seeking Orange Book deletion. 180-day exclusivity period begins on the date of first commercial marketing of either the NDA or ANDA drug. Exclusivity period is subject to forfeiture: if first application does not timely market the drug; if FDA approval is not granted within 30 months of filing the application; if applicant withdraws its application; if FDA deems application withdrawn; if applicant amends or withdraws the Paragraph IV Certification; - 2 -
3 if the patent that is the subject of the application expires; or, the application violates antitrust laws in a settlement agreement. The 180-day exclusivity period is shared by any Applicants who are the first to file and file on the same day. Any agreements between ANDA applicants or applicant and a brand name drug company must be filed within 10 days of execution of the agreement with the Assistant Attorney General and the FTC. Any applicant failing to provide such notification shall be subject to a civil fine of up to $11,000/day. Recent Case Law While no cases have interpreted the amended Statute yet, one case of note has been reported in 2004 dealing with the issues addressed by the changes: Purepac Pharmaceutical Co. v. TorPharm, Inc., 2004 U.S. App. LEXIS 767 (D.C. Cir. 2004) This case turned on two issues: an improper Orange Book listing and the Paragraph IV Certification notice requirement. Although the new Hatch-Waxman amendments would not have affected the outcome of the Court s finding on the Orange Book listing, it could have changed the decision regarding the notice dates. The Purepac case involves a dispute over the award of a 180-day exclusivity period for a generic version of the drug Neurontin, the patent for which was assigned by Warner-Lambert to Pfizer. Initially, the dispute centered on a method-of-use patent for the drug and ANDA applications filed by both Purepac Pharmaceutical Company and TorPharm, Inc. that sought approval for a generic form of the drug to treat epilepsy. After considerable litigation over the matter, Pfizer voluntarily withdrew this initial patent from the Orange Book. This resulted in neither Purepac nor TorPharm receiving the much sought-after exclusivity period from the FDA to market the generic drug. However, in the meantime, another Warner-Lambert/Pfizer patent issued for the composition and formulation of the drug, which, again, was listed in the FDA s Orange Book. Both Purepac and TorPharm amended their ANDA application to include Section IV certifications for the new patent. Purepac sent the statutorily required notice to Pfizer on June 13, 2003, two-and-one-half weeks after it had amended its ANDA application. TorPharm filed its amended ANDA and sent notice on the same day, June 13. However, the FDA considered TorPharm s application to have been filed on June 16, the date the FDA received it. Accordingly, the FDA awarded the 180-day exclusivity period to Purepac, and TorPharm appealed. In upholding the district court s finding that the FDA s award was correct, the U.S. Court of Appeals for the District of Columbia determined that the decision to award Purepac the exclusivity period was neither arbitrary or capricious. While Purepac had not complied with the statutory requirement for simultaneously filing an ANDA with a Section IV certification and giving notice, the FDA found Purepac s ANDA application to be effective on the date it gave the notice, June 13. The Statute now clarifies that there is no independent cause of action for a claim against an NDA holder to correct or delete information submitted to the FDA for an Orange Book listing that the patent does not claim either the drug for which the application was approved or the approved method of using the drug. However, Purepac did not sue the holder. Rather, it sued the FDA for rejection of its Section viii statement. This action would still be permissible with the 2003 changes. However, the issue of the timing of the notices would have been a non-issue for the Court and the applicants as the amended Statute now specifically addresses the timing of certification notices. Notices are timely given if - 3 -
4 not later than 20 days after the date of the postmark on the notice with which the Secretary informs the applicant that the application has been filed. 2 Or, if an application is amended or supplemented to include Paragraph IV Certification, then notice must be given at the time the applicant files the amendment or supplement. 3 Declaratory Judgment Jurisdiction While the new amendments specifically provide that a declaratory judgment (DJ) action is available to the applicant, it also, arguably, leaves applicants in the same position as before. A DJ action is available to the extent consistent with the Constitution. 4 This right has been varyingly interpreted by different courts. In Dr. Reddy s Laboratories, Ltd. v. Pfizer, Inc., 2003 WL (D.N.J. 2003), the court found that because the plaintiff was unable to show to a sufficient degree that the defendant intended to enforce its patent, there was no right to a DJ action. In explaining the court s decision, Judge Pisano stated that, to support a DJ action, a plaintiff is required to show (1) an explicit threat or action by the patentee, which creates a reasonable apprehension... that it [the plaintiff] will face an infringement suit, and (2) present activity which could constitute infringement... Id. at 2, citing to Amana Refrigeration, Inc. v. Quadlux, Inc., 172 F.3d 852, 855 (Fed. Cir. 1999). Dr. Reddy was able to only prove the second prong by virtue of the fact that the act of filing an ANDA application is defined in the Hatch-Waxman Act as an act of infringement. 5 The Court found the evidence submitted to prove the first prong a direct communication from the defendant refusing to assure Dr. Reddy that it would not sue was insufficient to prove an intent to enforce its patent. Judge Stearns in Teva Pharmaceuticals USA, Inc. V. Pfizer, Inc., 69 U.S.P.Q. 2d 1791 (D. Mass. 2003) rendered a similar opinion and decision against Teva. Again, in finding that the court had no jurisdiction, the deciding factor was the plaintiff s failure to present adequate evidence for the Court to find that there was an actual controversy. Id. at However, in Teva Pharmaceuticals USA, Inc., v. Abbott Laboratories, 301 F. Supp. 2d 819 (N.D. Ill. E. Div. 2004), Judge Lefkow found that the Court did have jurisdiction. In this case, Teva argued that it reasonably apprehended a patent infringement suit because: defendant had refused to furnish a covenant not to sue; defendant had filed against a Teva affiliate in Canada where the same drug was at issue; and, defendant had a history of filing infringement actions against Teva regarding its generic marketing endeavors. Judge Lefkow found that this evidence was sufficient to find an actual controversy. It seems unlikely, given these three recent decisions, that the specific grant of the right to file a DJ action in the amendments to the Hatch-Waxman Act will result in any significant changes in court decisions. The requirements for an actual controversy to give a court jurisdiction remain the same. Antitrust Another area with which the courts have been dealing is the issue of what type of settlement is acceptable and what type will constitute a violation of antitrust laws. The recent case law in the area of the antitrust aspect of ANDA settlements warrants an entire paper devoted to the issue. In brief, it seems certain that because of the new Hatch-Waxman requirements to provide notice to the FTC of any settlement agreements, drug companies can expect even closer scrutiny of all such agreements. Importance of Changes The amendments do clarify certain issues that have been raised during the processing and litigation of the ANDA applications. However, it seems that there is still considerable opportunity for the parties to disagree and to seek relief from the courts. It will be instructive to review new cases as they progress through the FDA approval process and through the court system. * * * * * * * - 4 -
5 Reed Smith, a leading global law firm with nearly 1,000 lawyers located in 16 U.S. and two U.K. cities, represents Fortune 100 as well as mid-market and emerging companies. Clients include technology companies and entrepreneurs, financial services firms, life sciences companies and health care providers and insurers, communications companies, manufacturers, universities, non-profit organizations, real estate developers, and municipalities throughout the United States, the United Kingdom, and in 40 other countries. For more information, please visit reedsmith.com U.S.C.S. 355 (2004). Title XI, Subtitle A, Section 1101(a)(1)(B)(ii)(I). Title XI, Subtitle A, Section 1101(a)(1)(B)(ii)(II). Title XI, Subtitle A, Section 1101(d)(5). 35 U.S.C. 271 (e)(2)(a)
From PLI s Program New Strategies Arising from the Hatch-Waxman Amendments #4888
From PLI s Program New Strategies Arising from the Hatch-Waxman Amendments #4888 New Strategies Arising From the Hatch-Waxman Amendments Practicing Law Institute Telephone Briefing May 12, 2004 I. INTRODUCTION
More informationLitigation Webinar Series. Hatch-Waxman 101. Chad Shear Principal, San Diego
Litigation Webinar Series Hatch-Waxman 101 Chad Shear Principal, San Diego 1 Overview Hatch-Waxman Series Housekeeping CLE Contact: Jane Lundberg lundberg@fr.com Questions January 25, 2018 INSIGHTS Litigation
More informationRecent developments in US law: Remedies and damages for improper patent listings in the FDA s Orange Book
Daniel G. Brown is a partner in the New York law firm Frommer Lawrence & Haug, LLP, and practises extensively in the Hatch Waxman area. He has been practising in New York since 1993 in the patent and intellectual
More informationCaraco V. Novo Nordisk: Antitrust Implications
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Caraco V. Novo Nordisk: Antitrust Implications Law360,
More informationPay-for-Delay Settlements: Antitrust Violation or Proper Exercise of Pharmaceutical Patent Rights?
Pay-for-Delay Settlements: Antitrust Violation or Proper Exercise of Pharmaceutical Patent Rights? By Kendyl Hanks, Sarah Jacobson, Kyle Musgrove, and Michael Shen In recent years, there has been a surge
More informationSome Declaratory Judgment Guidance For ANDA Litigants
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Some Declaratory Judgment Guidance For ANDA Litigants
More informationCase: 1:16-cv Document #: 1 Filed: 03/09/16 Page 1 of 13 PageID #:1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION
Case: 1:16-cv-02988 Document #: 1 Filed: 03/09/16 Page 1 of 13 PageID #:1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION TORRENT PHARMACEUTICALS LIMITED, and TORRENT PHARMA
More informationPENDING LEGISLATION REGULATING PATENT INFRINGEMENT SETTLEMENTS
PENDING LEGISLATION REGULATING PATENT INFRINGEMENT SETTLEMENTS By Edward W. Correia* A number of bills have been introduced in the United States Congress this year that are intended to eliminate perceived
More informationPharmaceutical Product Improvements and Life Cycle Management Antitrust Pitfalls 1
Pharmaceutical Product Improvements and Life Cycle Management Antitrust Pitfalls 1 The terms product switching, product hopping and line extension are often used to describe the strategy of protecting
More informationCase 3:11-cv JAP -TJB Document 32 Filed 07/06/11 Page 1 of 19 PageID: 530 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY
Case 3:11-cv-03111-JAP -TJB Document 32 Filed 07/06/11 Page 1 of 19 PageID: 530 NOT FOR PUBLICATION UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY : NOSTRUM PHARMACEUTICALS, LLC, : : Plaintiff,
More informationCase 3:14-cv MLC-TJB Document Filed 07/24/15 Page 2 of 16 PageID: 1111 TABLE OF CONTENTS INTRODUCTION... 1 BACKGROUND...
Case 3:14-cv-02550-MLC-TJB Document 100-1 Filed 07/24/15 Page 1 of 16 PageID: 1110 Keith J. Miller Michael J. Gesualdo ROBINSON MILLER LLC One Newark Center, 19th Floor Newark, New Jersey 07102 Telephone:
More informationUnited States Court of Appeals for the Federal Circuit
United States Court of Appeals for the Federal Circuit TEVA PHARMACEUTICALS USA, INC., THROUGH ITS GATE PHARMACEUTICALS DIVISION, Plaintiff-Appellant, v. EISAI CO., LTD. AND EISAI MEDICAL RESEARCH, INC.,
More informationAttachment C M AY Daniel J. Tomasch, Esq. Orrick, Herrington & Sutcliffe LLP 666 Fifth Ave. New York, NY Dear Mr.
DEPARTMENT OF Hr.PILTH & HUMAN SERVICES Health Service Public Food and Drug Administration R ockviue MD 20857 Daniel J. Tomasch, Esq. Orrick, Herrington & Sutcliffe LLP 666 Fifth Ave. New York, NY 10103
More informationIssue Brief for Congress Received through the CRS Web
Order Code IB10105 Issue Brief for Congress Received through the CRS Web The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents Updated November 25, 2002 Wendy H. Schacht and
More informationAttorneys for Defendants Watson Laboratories, Inc. and Watson Pharmaceuticals, Inc.
Case 2:10-cv-00080-FSH -PS Document 15 Filed 03/01/10 Page 1 of 14 HELLRING LINDEMAN GOLDSTEIN & SIEGAL LLP Matthew E. Moloshok, Esq. Robert S. Raymar, Esq. One Gateway Center Newark, New Jersey 07102-5386
More informationFDA Regulatory February 18, 2015
ROPES & GRAY ALERT FDA Regulatory February 18, 2015 Orange Book Patent Listing and Patent Certifications: Key Provisions in FDA s Proposed Regulations Implementing the Medicare Modernization Act of 2003
More informationPharmaceutical Pay for Delay Settlements
Pharmaceutical Pay for Delay Settlements UCIP Seminar 12 November 2012 www.morganlewis.com Outline Background Goals of the Hatch-Waxman Act Price Effects of Generic Entry Pay-for-Delay Patent Settlements
More informationCase 2:09-cv DMC-MF Document 17 Filed 04/20/2009 Page 1 of 28 : :
Case 2:09-cv-01302-DMC-MF Document 17 Filed 04/20/2009 Page 1 of 28 WINSTON & STRAWN LLP The Legal Center One Riverfront Plaza, 7th Floor Newark, New Jersey 07102 (973) 848-7676 James S. Richter Attorneys
More informationCase 1:10-cv JCJ Document 20 Filed 04/14/10 Page 1 of 12 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 110-cv-00137-JCJ Document 20 Filed 04/14/10 Page 1 of 12 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE MILLENNIUM PHARMACEUTICALS, INC. and SCHERING CORP., Plaintiffs, CIVIL ACTION
More informationTeva v. EISAI: What's the Real Controversy
Michigan Telecommunications and Technology Law Review Volume 18 Issue 1 2011 Teva v. EISAI: What's the Real Controversy Grace Wang University of Michigan Law School Follow this and additional works at:
More informationUnited States Court of Appeals for the Federal Circuit
Case: 14-1282 Case: CASE 14-1282 PARTICIPANTS Document: ONLY 44 Document: Page: 1 43 Filed: Page: 05/30/2014 1 Filed: 05/30/2014 2014-1282, -1291 United States Court of Appeals for the Federal Circuit
More informationPharmaceutical Patent Settlement Cases: Mixed Signals for Settling Patent Litigation
By Margaret J. Simpson Tel: 312 923-2857 Fax: 312 840-7257 E-mail: msimpson@jenner.com The following article originally appeared in the Spring 2004 issue of the Illinois State Bar Association s Antitrust
More informationHealth Care Law Monthly
Health Care Law Monthly February 2013 Volume 2013 * Issue No. 2 Contents: Copyright ß 2013 Matthew Bender & Company, Inc., a member of the Lexis- Nexis group of companies. All rights reserved. HEALTH CARE
More informationIff/]) FEB Gregory 1. Glover Pharmaceutical Law Group PC 900 Seventh Street, NW Suite 650 Washington, DC
DEPARTMENT OF HEALTH &. HUMAN SERVICES FEB 2 2 2011 Food and Drug Administration Rockville MD 20857 Gregory 1. Glover Pharmaceutical Law Group PC 900 Seventh Street, NW Suite 650 Washington, DC 20001-3886
More informationSUCCESSFULLY LITIGATING METHOD OF USE PATENTS IN THE U.S.
SUCCESSFULLY LITIGATING METHOD OF USE PATENTS IN THE U.S. The 10 th Annual Generics, Supergenerics, and Patent Strategies Conference London, England May 16, 2007 Provided by: Charles R. Wolfe, Jr. H. Keeto
More informationNo IN THE EISAI CO. LTD AND EISAI MEDICAL RESEARCH, INC., TEVA PHARMACEUTICALS USA, INC., through its GATE PHARMACEUTICALS Division,
No. 10-1070 ~[~ 2 7 7.i~[ IN THE EISAI CO. LTD AND EISAI MEDICAL RESEARCH, INC., Petitioners, TEVA PHARMACEUTICALS USA, INC., through its GATE PHARMACEUTICALS Division, Respondent. ON PETITION FOR A WRIT
More informationCase 1:07-cv RMU Document 81 Filed 06/27/2007 Page 1 of 14 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:07-cv-00579-RMU Document 81 Filed 06/27/2007 Page 1 of 14 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA MYLAN LABORATORIES, INC., et al., Plaintiffs, v. Civil Action No. 07-0579 (RMU
More informationON NOVEMBER 6, 2001, the U.S. Court of Appeals
21 Biotechnology Law Report 13 Number 1 (February 2002) Mary Ann Liebert, Inc. Brief Analysis of Recent Pharmaceutical/IP Decisions DAVID A. BALTO AMERICAN BIOSCIENCE, INC. V. THOMPSON 269 F.3D1077, 2001
More informationLife Sciences Industry Perspective on Declaratory Judgment Actions and Licensing Post-MedImmune. Roadmap for Presentation
Life Sciences Industry Perspective on Declaratory Judgment Actions and Licensing Post-MedImmune MedImmune: R. Brian McCaslin, Esq. Christopher Verni, Esq. March 9, 2009 clients but may be representative
More informationLooking Within the Scope of the Patent
Latham & Watkins Antitrust and Competition Practice Number 1540 June 25, 2013 Looking Within the Scope of the Patent The Supreme Court Holds That Settlements of Paragraph IV Litigation Are Subject to the
More informationCase 1:11-cv LPS Document 497 Filed 05/20/14 Page 1 of 9 PageID #: IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:11-cv-00704-LPS Document 497 Filed 05/20/14 Page 1 of 9 PageID #: 17900 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE AVANIR PHARMACEUTICALS, INC., AVANIR HOLDING COMPANY, AND
More informationHOGAN & HARTSON APR -9 P4 :18 BY HAND DELIVERY
HOGAN & HARTSON 2741 10 APR -9 P4 :18 Hogan & Hartson up Columbia Square 555 Thirteenth Street, NW Washington, DC 20004 +1.202.637.5600 Tel +1.202.637.5910 Fax www.hhlaw.com Philip Katz Partner 202.637.5632
More informationSupreme Court of the United States
NO. In the Supreme Court of the United States MYLAN PHARMACEUTICALS INC., v. Petitioner, APOTEX INC., Respondent. On Petition for Writ of Certiorari to the U.S. Court of Appeals for the Federal Circuit
More informationCase 1:14-cv IMK Document 125 Filed 06/16/14 Page 1 of 21 PageID #: 1959
Case 1:14-cv-00075-IMK Document 125 Filed 06/16/14 Page 1 of 21 PageID #: 1959 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF WEST VIRGINIA MYLAN PHARMACEUTICALS, INC., Plaintiff, WATSON
More informationIN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA. ) ) ) ) ) ) ) ) ) ) ) Plaintiffs, ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) Defendants.
Case 1:16-cv-01350 Document 1 Filed 06/28/16 Page 1 of 19 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA LANNETT COMPANY, INC., 13200 Townsend Road, Philadelphia, PA 19154 and LANNETT
More informationNo FOREST LABORATORIES, INC., FORES~LASO~TO~S Hot~mes, L~., ~D H. LU~.CK A/S, Petitioners,
No. 08-624 FOREST LABORATORIES, INC., FORES~LASO~TO~S Hot~mes, L~., ~D H. LU~.CK A/S, Petitioners, CARACO PHARI~CEUTICAL LABORATORIES, L~D., Respondent. On Petition for Writ of Certiorari To the United
More informationORDER GRANTING IN PART AND DENYING IN PART MOTION TO TRANSFER OR STAY
Pfizer Inc. et al v. Sandoz Inc. Doc. 50 Civil Action No. 09-cv-02392-CMA-MJW IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO Judge Christine M. Arguello PFIZER, INC., PFIZER PHARMACEUTICALS,
More informationCase 1:16-cv UNA Document 1 Filed 09/30/16 Page 1 of 11 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:16-cv-00886-UNA Document 1 Filed 09/30/16 Page 1 of 11 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PFIZER INC. and UCB PHARMA GMBH, v. Plaintiffs, AUROBINDO PHARMA
More informationCase 1:18-cv UNA Document 1 Filed 03/27/18 Page 1 of 87 PageID #: 4 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:18-cv-00466-UNA Document 1 Filed 03/27/18 Page 1 of 87 PageID #: 4 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE GILEAD SCIENCES, INC. and GILEAD PHARMASSET LLC, Plaintiffs, v.
More informationWe have carefully considered the Petition.! For the reasons described below, the Petition is granted.
DEPARTMENT OF HEALTH &. HUMAN SERVICES... -------------_._- Food and Drug Administration Rockville MD 20857 JUN 17 2010. Pankaj Dave, Ph.D. Vice President, Regulatory Affairs Navinta LLC 1499 Lower Ferry
More informationThe Hatch-Waxman Act and Market Exclusivity for Generic Manufacturers: An Entitlement or an Incentive
Chicago-Kent Law Review Volume 81 Issue 2 Symposium: Secrecy in Litigation Article 13 April 2006 The Hatch-Waxman Act and Market Exclusivity for Generic Manufacturers: An Entitlement or an Incentive Ashlee
More informationSupreme Court Invites Solicitor General s View on Safe Harbor of the Hatch-Waxman Act
Supreme Court Invites Solicitor General s View on Safe Harbor of the Hatch-Waxman Act Prepared By: The Intellectual Property Group On June 25, 2012, the United States Supreme Court invited the Solicitor
More informationCase 1:12-cv SLR Document 18 Filed 08/27/12 Page 1 of 17 PageID #: 71 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:12-cv-00809-SLR Document 18 Filed 08/27/12 Page 1 of 17 PageID #: 71 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PFIZER INC., WYETH LLC, WYETH PHARMACEUTICALS INC., and PF PRISM
More informationIncreased Scrutiny of Reverse Payment Settlements: Recent Cases in E.D. of PA and 2nd Circuit Suggest Change May Be Ahead for Pharma Clients
Increased Scrutiny of Reverse Payment Settlements: Recent Cases in E.D. of PA and 2nd Circuit Suggest Change May Be Ahead for Pharma Clients By Francis P. Newell and Jonathan M. Grossman Special to the
More informationCase 3:12-cv PGS-LHG Document 1 Filed 06/25/12 Page 1 of 41 PageID: 1
Case 3:12-cv-03893-PGS-LHG Document 1 Filed 06/25/12 Page 1 of 41 PageID: 1 Liza M. Walsh CONNELL FOLEY LLP 85 Livingston Avenue Roseland, New Jersey 07068 (973) 535-0500 Of Counsel: Dimitrios T. Drivas
More informationReverse Payment Settlements In Pharma Industry: Revisited
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Reverse Payment Settlements In Pharma Industry: Revisited
More informationIn the Supreme Court of the United States
No. 15-1055 In the Supreme Court of the United States SMITHKLINE BEECHAM CORPORATION, D/B/A GLAXOSMITHKLINE, ET AL., PETITIONERS v. KING DRUG COMPANY OF FLORENCE, INC., ET AL. ON PETITION FOR A WRIT OF
More informationPOST-MEDIMMUNE DEVELOPMENTS REGARDING DECLARATORY JUDGMENT JURISDICTION
POST-MEDIMMUNE DEVELOPMENTS REGARDING DECLARATORY JUDGMENT JURISDICTION The Federal Circuit's Recent SanDisk and Teva Pharmaceuticals Decisions On March 26 and 30, the U.S. Court of Appeals for the Federal
More informationCase 1:16-cv RBK-JS Document 1 Filed 06/30/16 Page 1 of 14 PageID: 1
Case 1:16-cv-03910-RBK-JS Document 1 Filed 06/30/16 Page 1 of 14 PageID: 1 John E. Flaherty Ravin R. Patel McCARTER & ENGLISH LLP Four Gateway Center 100 Mulberry St. Newark, NJ 07102 (973) 622-4444 Attorneys
More informationStatus Quo at the PTAB for Now: Supreme Court Makes No Change to IPR; Judicial Review and Claim Construction Standard Remain the Same
Status Quo at the PTAB for Now: Supreme Court Makes No Change to IPR; Judicial Review and Claim Construction Standard Remain the Same CLIENT ALERT June 30, 2016 Maia H. Harris harrism@pepperlaw.com Frank
More informationUNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY
Case 2:06-cv-03462-WJM-MF Document 161 Filed 10/20/16 Page 1 of 7 PageID: 5250 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY DAIICHI SANKYO, LIMITED and DAIICHI SANKYO, INC., v. Plaintiffs
More informationIn ThIs Issue. What s in a Name? Quantifying the Economic Value of Label Information
AvAilAble Online Free to MeMbers www.fdli.org july/august 2015 A PublicAtion of the food And drug law institute In ThIs Issue What s in a Name? Quantifying the Economic Value of Label Information by Anthony
More informationCase 1:16-cv UNA Document 1 Filed 03/31/16 Page 1 of 12 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:16-cv-00207-UNA Document 1 Filed 03/31/16 Page 1 of 12 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE GALDERMA LABORATORIES, L.P.; NESTLÉ SKIN HEALTH S.A.; and TCD
More informationDelayed Access to Generic Medicine: A Comment on the Hatch-Waxman Act and the "Approval Bottleneck
Fordham Law Review Volume 78 Issue 2 Article 16 2009 Delayed Access to Generic Medicine: A Comment on the Hatch-Waxman Act and the "Approval Bottleneck Ankur N. Patel Recommended Citation Ankur N. Patel,
More informationMay 2003 Bulletin Homeland Security Update: Continuous Challenges Lie Ahead
May 2003 Bulletin 03-42 Homeland Security Update: Continuous Challenges Lie Ahead If you have questions or would like additional information on the material covered in this Bulletin, please contact the
More informationCase 1:16-cv UNA Document 1 Filed 04/07/16 Page 1 of 17 PageID #: 1 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ) ) ) ) ) ) ) ) )
Case 1:16-cv-00237-UNA Document 1 Filed 04/07/16 Page 1 of 17 PageID #: 1 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE FRESENIUS KABI USA, LLC, Plaintiff, v. MAIA PHARMACEUTICALS, INC., Defendant.
More informationCase 1:07-cv RMU Document 71-2 Filed 05/08/2007 Page 1 of 6. ANDA , Amlodipine Besylate Tablets, 2.5 mg, 5 mg, and 10 mg.
Case 1:07-cv-00579-RMU Document 71-2 Filed 05/08/2007 Page 1 of 6 DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 76-719, Amlodipine Besylate Tablets, 2.5 mg, 5 mg, and 10 mg. SENT BY FACSIMILE AND U.S. MAIL
More informationProduct Improvements and Life Cycle Management Antitrust Pitfalls
Product Improvements and Life Cycle Management Antitrust Pitfalls NJ IP Law Association's 26th Annual Pharmaceutical/Chemical Patent Practice Update Paul Ragusa December 5, 2012 2012 Product Improvements
More informationFDA, PATENT TERM EXTENSIONS AND THE HATCH WAXMAN ACT. Dr.Sumesh Reddy- Dr. Reddys Lab Hyderabad-
FDA, PATENT TERM EXTENSIONS AND THE HATCH WAXMAN ACT Dr.Sumesh Reddy- Dr. Reddys Lab Hyderabad- FDA Regulatory approval-time and cost Focus of FDA approval process-safety and efficacy Difference between
More information2010 Thomson Reuters. No Claim to Orig. US Gov. Works.
Page 1 United States Court of Appeals, Federal Circuit. CARACO PHARMACEUTICAL LABORATO- RIES, LTD., Plaintiff-Appellant, v. FOREST LABORATORIES, INC., Forest Laboratories Holdings, Ltd., and H. Lundbeck
More informationPatent Infringement and Experimental Use Under the Hatch-Waxman Act: Current Issues
Patent Infringement and Experimental Use Under the Hatch-Waxman Act: Current Issues John R. Thomas Visiting Scholar February 9, 2012 CRS Report for Congress Prepared for Members and Committees of Congress
More informationCase 1:10-cv UNA Document 1 Filed 10/05/10 Page 1 of 20
Case 1:10-cv-00852-UNA Document 1 Filed 10/05/10 Page 1 of 20 Case 1:10-cv-00852-UNA Document 1 Filed 10/05/10 Page 2 of 20 4. Plaintiff Allergan Sales, LLC is a corporation organized and existing under
More informationA. ANDAs and Eligibility for 180-day Exclusivity
DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Rockville, MD 20857 SENT VIA ELECTRONIC MAIL Dear Celecoxib ANDA Applicant: This letter addresses the legal and regulatory scheme governing
More informationHatch-Waxman Patented v. Generic Drugs: Regulatory, Legislative and Judicial Developments
Santa Clara High Technology Law Journal Volume 20 Issue 3 Article 4 January 2004 Hatch-Waxman 2003 - Patented v. Generic Drugs: Regulatory, Legislative and Judicial Developments Richard J. Smith Follow
More informationCase 3:06-cv JSW Document 203 Filed 02/12/2008 Page 1 of 6
Case :0-cv-00-JSW Document 0 Filed 0//00 Page of 0 0 R. Scott Jerger (pro hac vice (Oregon State Bar #0 Field Jerger LLP 0 SW Alder Street, Suite 0 Portland, OR 0 Tel: (0 - Fax: (0-0 Email: scott@fieldjerger.com
More informationSupreme Court of the United States
No. 15-1055 IN THE Supreme Court of the United States SMITHKLINE BEECHAM CORPORATION, D/B/A GLAXOSMITHKLINE; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS, USA, Petitioners, v. KING DRUG COMPANY
More informationCase 1:16-cv UNA Document 1 Filed 01/15/16 Page 1 of 13 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:16-cv-00015-UNA Document 1 Filed 01/15/16 Page 1 of 13 PageID #: 1 PROSTRAKAN, INC. and STRAKAN INTERNATIONAL S.á r.l., IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE v. Plaintiffs,
More informationCase 1:18-cv UNA Document 1 Filed 10/22/18 Page 1 of 14 PageID #: 1
Case 1:18-cv-01639-UNA Document 1 Filed 10/22/18 Page 1 of 14 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE MILLENNIUM PHARMACEUTICALS, INC., v. Plaintiff, HETERO LABS LIMITED
More informationUNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY
UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY ) THE UNITED STATES OF AMERICA ) and THE BOARD OF TRUSTEES OF ) THE UNIVERSITY OF ILLINOIS, ) Civil Action No. ) Plaintiffs, ) COMPLAINT FOR ) PATENT
More informationCase 1:18-cv UNA Document 1 Filed 01/19/18 Page 1 of 14 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:18-cv-00117-UNA Document 1 Filed 01/19/18 Page 1 of 14 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE TEVA PHARMACEUTICALS INTERNATIONAL GMBH, CEPHALON, INC., and EAGLE
More information5 Red Flags In Pharmaceutical Settlements
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com 5 Red Flags In Pharmaceutical Settlements Law360,
More informationCase 1:18-cv UNA Document 1 Filed 01/30/18 Page 1 of 8 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:18-cv-00171-UNA Document 1 Filed 01/30/18 Page 1 of 8 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE FOREST LABORATORIES HOLDINGS, LTD., ALLERGAN USA, INC., ALLERGAN
More informationPATENT, TRADEMARK & COPYRIGHT!
A BNA s PATENT, TRADEMARK & COPYRIGHT! JOURNAL Reproduced with permission from BNA s Patent, Trademark & Copyright Journal, 81 PTCJ 36, 11/05/2010. Copyright 2010 by The Bureau of National Affairs, Inc.
More informationUnited States District Court EASTERN DISTRICT OF TEXAS TYLER DIVISION
Case 6:11-cv-00441-MHS Document 304 Filed 01/13/14 Page 1 of 5 PageID #: 8335 United States District Court EASTERN DISTRICT OF TEXAS TYLER DIVISION ALLERGAN, INC. v. Cause No. 6:11-cv-441 Consolidated
More informationALLERGAN, INC. and ALLERGAN SALES, INC., ALCON LABORATORIES, INC., ALCON RESEARCH, LTD., and ALCON UNIVERSAL, LTD.,
UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT 02-1449 ALLERGAN, INC. and ALLERGAN SALES, INC., Plaintiffs- Appellants, v. ALCON LABORATORIES, INC., ALCON RESEARCH, LTD., and ALCON UNIVERSAL, LTD.,
More informationTC Heartland s Restraints On ANDA Litigation Jurisdiction
Portfolio Media. Inc. 111 West 19 th Street, 5th Floor New York, NY 10011 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com TC Heartland s Restraints On ANDA Litigation
More informationSupreme Court of the United States
NO. 15-307 In the Supreme Court of the United States MYLAN PHARMACEUTICALS INC., v. Petitioner, APOTEX INC., Respondent. On Petition for Writ of Certiorari to the U.S. Court of Appeals for the Federal
More informationCase 1:10-mc CKK -AK Document 31 Filed 07/13/10 Page 1 of 12 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:10-mc-00289-CKK -AK Document 31 Filed 07/13/10 Page 1 of 12 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA FEDERAL TRADE COMMISSION, Petitioner, v. PAUL M. BISARO, Misc. No. 10-289 (CKK)(AK)
More informationo 1205 Culbreth Dr., Suite 200, Wilmington, NC Phone : Facsimile :
Osmotica Pharmaceutical 1?54,Lt. 27 P2 :05 BY HAND DELIVERY Division of Dockets Management Food and Drug Administration Department of Health and Human Services 563"0 Fishers Lane, Room 1061 Rockville,
More information(4- I. Background. Douald O. Beers Arnold & Porter LLP 555 Twelfth Street, N.W. Washington, D.c
(4- DEPARTMENT OF HEALTH &. HUMAN SERVICES Public Health Service Food and Drug Administration Rockville MD 20857 Douald O. Beers Arnold & Porter LLP 555 Twelfth Street, N.W. Washington, D.c. 20004-1206
More informationWhere Can Hatch-Waxman and BPCIA Cases Stick After TC Heartland LLC v. Kraft Foods Group Brands LLC?
9 June 2017 Practice Groups: Pharma and BioPharma Litigation IP Litigation Where Can Hatch-Waxman and BPCIA Cases Stick After TC Heartland LLC v. Kraft Foods Group Brands LLC? By Elizabeth Weiskopf, Kenneth
More informationThe ITC's Potential Role In Hatch-Waxman Litigation
Portfolio Media. Inc. 111 West 19 th Street, 5th Floor New York, NY 10011 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com The ITC's Potential Role In Hatch-Waxman
More informationA. Bayer's New Drug Application for Precose
DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Rockville, MD 20857 William A. Rakoczy, Esq. Rakoczy, Molino, Mazzochi & Siwik, LLP 6 West Hubbard St. Suite 500 Chicago, IL 60610 Dear
More informationNo IN THE MYLAN LABORATORIES, INC., MYLAN PHARMACEUTICALS, INC., & UDL LABORATORIES, INC.,
11 No. 08-1461 IN THE MYLAN LABORATORIES, INC., MYLAN PHARMACEUTICALS, INC., & UDL LABORATORIES, INC., v. Petitioners, TAKEDA CHEMICAL INDUSTRIES, LTD. & TAKEDA PHARMACEUTICALS NORTH AMERICA, INC., Respondents.
More informationUnited States Court of Appeals for the Federal Circuit
United States Court of Appeals for the Federal Circuit 2009-1071 ELI LILLY AND COMPANY, Plaintiff-Appellee, v. TEVA PHARMACEUTICALS USA, INC., Defendant-Appellant. Charles E. Lipsey, Finnegan, Henderson,
More informationCase 1:17-cv UNA Document 1 Filed 10/20/17 Page 1 of 8 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:17-cv-01481-UNA Document 1 Filed 10/20/17 Page 1 of 8 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE FOREST LABORATORIES, LLC, FOREST LABORATORIES HOLDINGS, LTD., ALLERGAN
More informationCase 1:18-cv IMK Document 250 Filed 08/30/18 Page 1 of 11 PageID #: 2905 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:18-cv-00226-IMK Document 250 Filed 08/30/18 Page 1 of 11 PageID #: 2905 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ALLERGAN SALES, LLC, FOREST LABORATORIES HOLDINGS, LTD.,
More informationCase 1:09-cv UNA Document 1 Filed 07/13/2009 Page 1 of 17
Case 1:09-cv-00511-UNA Document 1 Filed 07/13/2009 Page 1 of 17 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ALLERGAN, INC., ALLERGAN USA, INC., ALLERGAN SALES, LLC, ENDO PHARMACEUTICALS
More informationCase 1:09-cv JJF Document 36 Filed 02/09/10 Page 1 of 22 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:09-cv-00651-JJF Document 36 Filed 02/09/10 Page 1 of 22 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE BRISTOL-MYERS SQUIBB CO., and BRISTOL-MYERS SQUIBB PHARMA CO. Plaintiffs,
More informationTHE SAFE HARBOR PROVISION OF HATCH-WAXMAN IS THERE A HOLE IN THE SAFETY NET?
THE SAFE HARBOR PROVISION OF HATCH-WAXMAN IS THERE A HOLE IN THE SAFETY NET? The Drug Price Competition and Patent Term Restoration Act of 1984 (also known as the Hatch-Waxman Act) was enacted for the
More informationCase 3:10-cv JAP -TJB Document 1 Filed 08/16/10 Page 1 of 13 PageID: 1
Case 3:10-cv-04205-JAP -TJB Document 1 Filed 08/16/10 Page 1 of 13 PageID: 1 John E. Flaherty Jonathan M.H. Short McCARTER & ENGLISH, LLP Four Gateway Center 100 Mulberry Street Newark, New Jersey 07109
More informationSupreme Court of the United States
No. 10-844 IN THE Supreme Court of the United States CARACO PHARMACEUTICAL LABORATORIES, LTD., et al., Petitioners, v. NOVO NORDISK A/S, et al., Respondents. On Writ of Certiorari to the United States
More informationS To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market.
II 111TH CONGRESS 1ST SESSION S. 369 To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. IN THE SENATE OF THE UNITED STATES
More informationCase 1:99-cv DLC Document 101 Filed 08/05/13 Page 1 of 10
Case 199-cv-09887-DLC Document 101 Filed 08/05/13 Page 1 of 10 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK -------------------------------------- ASTRA AKTIEBOLAG, et al., -v- Plaintiffs,
More informationIN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION COMPLAINT FOR PATENT INFRINGEMENT
IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION GALDERMA LABORATORIES, L.P., GALDERMA S.A., and GALDERMA RESEARCH & DEVELOPMENT, S.N.C., v. Plaintiffs, ACTAVIS MID
More informationThe Korean Drug Approval-Patent Linkage System: A Comparison with the US Hatch-Waxman Act
FEBRUARY 2015 The Korean Drug Approval-Patent Linkage System: A Comparison with the US Hatch-Waxman Act Authors: Ki Young Kim, Hyunsuk Jin, Samuel SungMok Lee Pursuant to the implementation of the Korea-US
More informationIN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE MALLINCKRODT IP, MALLINCKRODT HOSPITAL PRODUCTS INC., and SCR PHARMATOP, v. Plaintiffs, C.A. No. 17-365-LPS B. BRAUN MEDICAL INC.,. Defendant.
More informationCase 1:10-cv UNA Document 1 Filed 10/25/10 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ) ) ) ) ) ) ) ) ) ) ) )
Case 1:10-cv-00912-UNA Document 1 Filed 10/25/10 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ABBOTT LABORATORIES and WISCONSIN ALUMNI RESEARCH FOUNDATION, v. Plaintiffs,
More informationDIRECT PURCHASERS STANDING TO SUE FOR WALKER PROCESS FRAUD IN RE: DDAVP DIRECT PURCHASER ANTITRUST LITIGATION
DIRECT PURCHASERS STANDING TO SUE FOR WALKER PROCESS FRAUD IN RE: DDAVP DIRECT PURCHASER ANTITRUST LITIGATION Rick Duncan Denise Kettleberger Melina Williams Faegre & Benson, LLP Minneapolis, Minnesota
More informationCase 1:18-cv LPS Document 1 Filed 01/12/18 Page 1 of 17 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:18-cv-00092-LPS Document 1 Filed 01/12/18 Page 1 of 17 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE H. LUNDBECK A/S, TAKEDA PHARMACEUTICAL COMPANY LTD., TAKEDA PHARMACEUTICALS
More information